Selected article for: "active site and drug resistance"
Author: Minchen Chien; Thomas K. Anderson; Steffen Jockusch; Chuanjuan Tao; Shiv Kumar; Xiaoxu Li; James J. Russo; Robert Kirchdoerfer; Jingyue Ju
Title: Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase
  • Document date: 2020_3_20
    • ID: 8prn86g6_2_1
    Snippet: form of TAF, Tenofovir diphosphate, is much smaller than natural nucleoside triphosphates, we expect that it can easily fit within the active site of SARS-CoV-2 RdRp. As a noncyclic nucleotide, TFV-DP lacks a normal sugar ring configuration, and thus we reasoned that it is unlikely to be recognized by 3'-. CC-BY-NC-ND 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-r.....
    Document: form of TAF, Tenofovir diphosphate, is much smaller than natural nucleoside triphosphates, we expect that it can easily fit within the active site of SARS-CoV-2 RdRp. As a noncyclic nucleotide, TFV-DP lacks a normal sugar ring configuration, and thus we reasoned that it is unlikely to be recognized by 3'-. CC-BY-NC-ND 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.18.997585 doi: bioRxiv preprint exonucleases involved in SARS-CoV-2 proofreading processes, decreasing the likelihood of developing resistance to the drug. 17

    Search related documents:
    Co phrase search for related documents
    • active site and easily SARS RdRp active site fit: 1
    • active site and natural nucleoside triphosphate: 1, 2
    • active site and nucleoside triphosphate: 1, 2, 3
    • active site and proofreading process: 1
    • active site and SARS RdRp active site: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • active site and SARS RdRp active site fit: 1
    • active site and sugar ring: 1, 2, 3
    • active site and TAF form: 1, 2
    • active site and Tenofovir diphosphate: 1, 2, 3
    • active site and Tenofovir diphosphate TAF form: 1
    • drug resistance and easily SARS RdRp active site fit: 1
    • drug resistance and natural nucleoside triphosphate: 1
    • drug resistance and nucleoside triphosphate: 1, 2
    • drug resistance and SARS RdRp active site: 1
    • drug resistance and SARS RdRp active site fit: 1
    • drug resistance and sugar ring: 1
    • drug resistance and TAF form: 1
    • drug resistance and Tenofovir diphosphate: 1, 2
    • drug resistance and Tenofovir diphosphate TAF form: 1